ReWalk Robotics will unveil its exoskeleton at the upcoming Abilities Expo in New York May 5th to May 7th. The technology can help individuals with spinal cord injury access environments otherwise inaccessible due to stairs or curbs.

In March 2023, the U.S. Food and Drug Administration (FDA) granted clearance for the exoskeleton for use on stairs and curbs. This made it the first personal exoskeleton in the US to receive FDA backing for this kind of use.

The expanded feature, which enables spinal cord injury patients to access a wider range of environments, has already been available for some years to patients with paralysis in Europe since its initial CE clearance. Data over 18,000 stair steps from 47 users in Europe was used as support for the FDA submission.

“We are excited to showcase the life-changing functionality and access that our stairs technology provides those with a ReWalk Personal Exoskeleton,” said Larry Jasinski, ReWalk CEO.

“This is truly a first-of-its-kind development, and we are pleased to have actual ReWalk users available to demonstrate not only how this technology works, but also what it means for them in terms of increasing their freedom of mobility and access in their everyday lives.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.